<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058278</url>
  </required_header>
  <id_info>
    <org_study_id>DR-002-1213</org_study_id>
    <nct_id>NCT01058278</nct_id>
  </id_info>
  <brief_title>Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma</brief_title>
  <acronym>SLT</acronym>
  <official_title>Impact of the Post-operative Treatment on the Intraocular Pressure Post Selective Laser Trabeculoplasty (SLT) on Patients With Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Glaucoma Clinical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study's main objective is to assess if there is a significant difference between
      either of the treatments frequently used in post-op, namely a topic cortisone-based
      treatment, an non-steroidal anti-inflammatory drug (NSAID) or simply a placebo, in order to
      gain the best long term (6 months) efficacy of the SLT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The selective laser trabeculoplasty (SLT) is the laser treatment of choice for treating
      glaucoma. A There is however a controversy regarding the use of drops post-treatment. Indeed,
      some would prefer not to pharmacologically modulate the post-op inflammatory response which
      can be an integral part of the treatment by favouring the mobilisation of the macrophages
      which participate to the trabeculae &quot;cleaning&quot;. Others will prefer to calm the inflammatory
      reaction and choose an anti-inflammatory drug (either steroidal or non-steroidal).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure in the treated eye</measure>
    <time_frame>1 hour, 7 days, 1.5, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects (include a slight uveitis, oculary discomfort and a spike in intraocular pressure in the immediate post-op period)</measure>
    <time_frame>1 hour, 7 days, 1.5 months, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Glaucoma</condition>
  <condition>Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Prednisone acetate 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A topic cortisone-based treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diclofenac 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an non-steroidal anti-inflammatory drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pharmasciences DIN: 02229570</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective Laser trabeculoplasty</intervention_name>
    <description>The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.</description>
    <arm_group_label>Prednisone acetate 1%</arm_group_label>
    <arm_group_label>diclofenac 0.1%</arm_group_label>
    <arm_group_label>Artificial Tears</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from with primary open-angle glaucoma.

          -  Patients with IOP &gt; 21 mmHg, uncontrolled with medical treatment or due to
             non-compliance, or to whom this is the first glaucoma treatment.

          -  Patients &gt; 18 years old, able to consent.

          -  Patients consenting to the trial.

        Exclusion Criteria:

          -  Patients suffering from chronic glaucoma other than primary open-angle glaucoma

          -  Patients who had changes done to their anti-glaucoma treatments over the last 6 weeks
             or following the SLT

          -  Patients under oral corticosteroid treatment at the time of the operation or those who
             have stopped during the preceding month.

          -  Patients suffering from an important corneal disease which interferes with the
             capacity to visualize the entire trabeculae.

          -  Monophthalmic patients.

          -  Patients who already underwent a glaucoma treatment to the eye requiring treatment.

          -  Patients who already underwent a glaucoma treatment using SLT or ALT (Argon laser
             trabeculoplasty)

          -  Patients who underwent cataract surgery in the past 3 months.

          -  Pregnant patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Béatrice Des Marchais, FRCSC M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Quebec-Universite Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Béatrice Des Marchais</investigator_full_name>
    <investigator_title>Chercheure clinicienne associée</investigator_title>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Intraocular Pressure</keyword>
  <keyword>Trabeculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

